Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer

• Status: Unknown status
• Trial end date: 2020-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to use 18F-EF5 PET/CT scans to locate areas with low oxygen levels (hypoxia) in patients with recurrent and/or metastatic cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: British Columbia Cancer Agency
• Collaborator: Carraressi Foundation OVCARE

Criteria

Inclusion Criteria:

• Histologically confirmed, advanced metastatic or recurrent clear cell cancer of the ovary

• At least one index lesion measuring 2 cm in diameter

• Must be able to provide written informed consent, and willing to comply with protocol procedures of the study

• Off all active therapy for at least 4 weeks (cytotoxic chemotherapy, radiation, immune therapy, hormone therapy, clinical trials or new agents)

Exclusion Criteria:

• Renal failure (eGFR < 50mls/min)

• Patients with unknown primaries

• Previous history of cancer, except treated non-melanoma skin cancer, non-invasive breast cancer, non-invasive cervical cancer; or curatively treated solid cancer with no evidence of recurrence for more than 5 years.

• Receiving or had received active therapy in the form or chemotherapy or radiation within 4 weeks of the PET scan

• ECOG status ≥ 3

• Unable to tolerate a PET scan which involves an injection of radiopharmaceutical and lying flat and still for 30 minutes.

• Weight more than 204.5 kg (Physical Limitation of Imaging and Radiotherapy Couches) or cannot fit through the PET/CT machine (diameter 70cm).

• Patient is pregnant or breastfeeding